De manglende dataene: En gjennomsiktighetskrise i hjertet av Parkinsonsforskningen
Av hundrevis av kliniske studier for Parkinson som er fullført det siste tiåret, har bare én av tre rapportert resultatene sine offentlig, selv om føderal lov krever det. Ett hundre og tjueåtte studier har overskredet rapporteringsfristene. Tolv prosent forsvant simpelthen inn i statusen «ukjent». Tusenvis av pasienter stilte sine kropper, sitt håp og sin tid til rådighet. Dataene kan være tapt for vitenskapen for alltid.
Informasjonen i denne artikkelen er kun til opplysningsformål og er ikke ment som medisinsk rådgivning. Rådfør deg alltid med kvalifisert helsepersonell ved medisinske spørsmål.
Sammendrag
Denne artikkelen avslører en alvorlig gjennomsiktighetskrise i forskningen på Parkinsons sykdom: kun 34 % av kliniske studier fullført det siste tiåret har offentliggjort resultatene sine. Leserne vil lære: - **Omfanget:** 128 studier overskred rapporteringsfristene, og 12 % forsvant inn i statusen «ukjent». - **Den vitenskapelige kostnaden:** Skjulte data, spesielt negative resultater, fører til duplisering av innsats, bortkastet finansiering og stagnasjon i fremgangen. - **Det etiske bruddet:** Unnlatelse av å publisere resultater visker ut offeret til pasientfrivillige. Med lovende sykdomsmodifiserende medisiner som går inn i sluttfasen av studier, er det avgjørende å rette opp denne rapporteringssvikten for å akselerere fremtidige gjennombrudd.
When a person with Parkinson's disease enrolls in a clinical trial, they make a particular kind of bargain. They may submit to invasive procedures or endure months of detailed record-keeping. They accept the risks inherent in experimental treatments, including the possibility of no benefit or adverse effects. In exchange, they expect one thing: that whatever happens, science will learn from it.
For many Parkinson's patients over the past decade, the promise that science would learn from their participation has been jeopardized by a lack of transparency.
Of the hundreds of Parkinson's drug trials completed between 2015 and 2024, only about one in three has reported its results publicly, according to the most comprehensive decade-long analysis of the field to date. One hundred and twenty-eight trials are past their reporting deadlines. Twelve percent have lapsed into a status called, with unintentional poetry, "unknown." Their public record updates ceased. For many of these trials, their findings—whether positive, negative, or inconclusive—have not been made publicly available on ClinicalTrials.gov.
The Parkinson's research community appears to be approaching what some describe as a potential inflection point. After half a century without a single approved therapy that slows or halts the disease, a new generation of disease-modifying drugs is finally reaching late-stage trials. But beneath this optimism lies a quieter challenge: a systematic failure of trial reporting that risks undermining the full value of patient contributions, hindering scientific progress, and potentially slowing the pace of breakthroughs researchers are racing toward.
The Numbers Behind the Silence
The scale of the problem becomes clear in the granular accounting performed by Kevin McFarthing and colleagues, who have cataloged every Parkinson's drug trial registered on ClinicalTrials.gov for the past ten years. Their 2015–2024 longitudinal review documents 444 trials testing 281 distinct drug interventions—a remarkable mobilization of scientific effort. Yet when the authors examined how many of these completed studies had publicly reported their results, the answer was 34 percent.
McFarthing's 2024 update, which tracked 136 active trials, found that 41 percent of studies active at the start of 2023 had posted delays, with an average slippage of 10 months. Some trials have lapsed into 'unknown' status.
For a field that, despite decades of research, has yet to see an approved disease-modifying therapy, and where few candidates advance past early stages, the absence of data from even a single trial can be significant. Multiply that by hundreds of trials and the silence becomes deafening.
Why It Happens
This incomplete reporting can lead to an incomplete scientific record. Researchers planning new trials may struggle to learn from the outcomes of prior studies when those results are not publicly documented.
This matters enormously for a disease like Parkinson's, which has a diverse and evolving drug pipeline exploring various biological hypotheses. Consider the recent Phase 2b trial of Biogen and Denali's LRRK2 kinase inhibitor, known as Luma, which missed its primary endpoint in patients with idiopathic Parkinson's disease earlier this year. The result was disappointing, but it was also informative: the drug demonstrated more than 50 percent reduction in LRRK2 activity, validating target engagement even as the clinical benefit eluded researchers. The announcement of these top-line results allows the field to consider refining its hypothesis—perhaps LRRK2 inhibition will prove effective primarily in genetically defined patients, a question currently being explored in the ongoing Beacon trial.
Now imagine a parallel universe in which Luma's results were simply never released. The next sponsor might launch a similar trial, enroll similar patients, and potentially produce a similar outcome. Patients would volunteer again. Money would burn again. The cycle would continue.
What Is Lost
The costs of poor reporting compound across the pipeline. Hypotheses that have already been tested might be retested unnecessarily.
Despite the inherent challenges of drug development, the Parkinson's pipeline is robust and diverse, with many current therapeutic bets focusing on a set of key biological pathways according to recent analyses. Anti-inflammatory trials more than doubled between 2023 and 2024, many of them targeting the NLRP3 inflammasome. GBA-targeted trials also doubled. Alpha-synuclein remains an active target, with antibody approaches, such as Roche's prasinezumab, advancing to Phase 3 according to Simon Stott. Other novel approaches like RNA-directed therapies are also emerging.
The problem is especially acute for disease-modifying therapies, which face a punishing translational bottleneck. Although such therapies now dominate new trial registrations—surpassing symptomatic treatments for the first time after 2022—only 5 percent of disease-modifying trials reach Phase 3, compared with 17 percent of symptomatic ones. Every lost dataset from the early phases can make the climb to Phase 3 a little steeper.
The stakes are also human. Simon Stott has emphasized that even negative trials advance scientific understanding by refining hypotheses and improving future trial design. When those results are not made public, however, that learning is impeded. Patients who enroll in Parkinson's trials are not abstractions. They are people with a progressive, incurable neurological disease who have chosen to spend some of their remaining good years on the chance that their participation will help someone, eventually. When a trial's results disappear, that contribution is erased.
The Reformers and the Road Ahead
A transparent Parkinson's pipeline would look different from today's. It would post negative results as readily as positive ones. It would include detailed protocols, statistical analysis plans, and individual-participant data when patient privacy allows. It would treat reporting not as a regulatory afterthought but as a core ethical obligation to the patients who made the research possible.
The field is approaching what could be a genuine inflection point. Major late-stage readouts loom across multiple pathways: the Phase 3 prasinezumab trial in 900 alpha-synuclein patients, the Phase 3 ASPro-PD ambroxol trial with half of its 330 participants being GBA1 carriers, the NOPARK nicotinamide riboside trial targeting mitochondria, and the Phase 2a Beacon LRRK2 trial in genetically defined patients. Some of these will read out within the next two years; others not until 2030.
Whether these trials deliver the first disease-modifying therapy for Parkinson's, or merely add to the half-century of failures, their lessons must reach the broader scientific community. The patients who enrolled deserve at least that much. The next generation of patients, whose trials will be designed on the basis of these results, needs nothing less.
The Parkinson's pipeline has never been more diverse, more mechanistically ambitious, or more genuinely promising. It also has never been more dependent on a reporting infrastructure that, by the field's own accounting, is failing two-thirds of the time. Fixing the science of Parkinson's disease will require fixing the record of Parkinson's research first.
Også i Parkinsons sykdom
Leder: En ny start etter det tapte tiåret
I mai 2026 tegnet en rapport om fremdriften i Parkinson-forskningen et dystert bilde av resultatene av innsatsen i perioden 2014–2024. Utsiktene for det kommende tiåret er heldigvis mye lysere.
Bas Bloem: Eraen for persontilpasset Parkinsons har begynt
For en av verdens ledende Parkinsons-forskere, Bas Bloem, begynner fremtiden for feltet med et radikalt perspektivskifte: Parkinsons er ikke én sykdom, men millioner.
Claire Henchcliffe: Gjenoppbygger Parkinsons hjernen
Parkinson-behandling har hittil stort sett handlet om å erstatte tapt dopamin. Nevrolog Claire Henchcliffe bidrar til å teste en langt mer ambisiøs idé: å gjenoppbygge de skadede hjernekretsene selv.
